Lerdelimumab

Lerdelimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetTGF beta 2
Clinical data
ATC code
  • none
Legal status
Legal status
  • Development discontinued
Identifiers
CAS Number
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.

It was being developed to reduce scarring after glaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results for that condition.[2]

References

  1. ^ "Lerdelimumab". Drugs in R&D. 3 (2): 106–8. 1 February 2002. doi:10.2165/00126839-200203020-00006. PMID 12001808.
  2. ^ "CAT abandons Trabio after second clinical trial failure". The Pharma Letter. 28 March 2005.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.